B-cell type acute leukaemia
RecruitingOptimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy
Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy
- Disease:B-cell type acute leukaemia
- Substances:Fludarabine Phosphate
Germany- Participants:0–17 years · 18–64 years
- Substances:Fludarabine Phosphate
